Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 Net Margin % is 0.00% as of Jun. 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 948 Biotechnology companies, SILO Pharma ranks worse than 92.72% on this metric.
Net margin is calculated as Net Income divided by its Revenue. SILO Pharma's Net Income for the
three
months ended in Jun. 2026 was $-0.83 Mil. SILO Pharma's Revenue for the
three
months ended in Jun. 2026 was $0.00 Mil. Therefore, SILO Pharma's net margin for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for SILO Pharma's Net Margin % or its related term are showing as below:
SILO'
s Net Margin % Range Over the Past 10 Years
Min: -8281.48 Med: -5140.28 Max: 5498.59
Current: -8281.48
SILO's Net Margin % is ranked worse than 92.72% of 948
companies
in the Biotechnology industry
Industry Median: -75.55
vs SILO: -8281.48
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
SILO Pharma Net Margin % Related Terms
SILO Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for SILO Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a Net Margin % of 0.00% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on SILO Pharma and its competitors. According to the industry distribution chart, SILO Pharma ranks #879 out of 948 companies in the Biotechnology industry, placing it in the top 92.7%.
Is SILO Pharma's Net Margin % too high?
SILO Pharma's current Net Margin % is 0.00%. Based on the distribution chart, SILO Pharma ranks #879 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Net Margin % compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #879 out of 948 companies for Net Margin %. This places SILO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on SILO Pharma and its competitors. SILO Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Net Margin % is 0.00%. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For SILO Pharma (SILO), the current Net Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
Net Margin %: 0.00%
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
